December 21, 2017
Reuters Special Report: How Philip Morris is selling regulators on its hot new smoking device http://reut.rs/2Dm4euV
Philip Morris executives are traversing the globe to lobby health authorities on the benefits of iQOS, the little machine the tobacco giant says is key to the company's future. The novel argument: While iQOS uses tobacco, it shouldn't be categorized as a cigarette because it doesn't burn the leaf, a Reuters investigation published today shows.
For earlier stories in the series, please visit https://www.reuters.com/investigates/section/pmi/
December 21, 2017
The attached letter (reproduced below) has been submitted to the docket; the tracking number is 1k1-90fp-cqy1. A PDF of the letter is available here.
December 18, 2017
Mr. Mitchell Zeller
Director, Center for Tobacco Products
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Re: 82 FR 60206, Docket no. FDA-2017-N-4678, Modified Risk Tobacco Product Applications: Applications for Six Camel Snus Smokeless Tobacco Products Submitted by R.J. Reynolds Tobacco Company; Availability
Dear Mr. Zeller:
Today, December 18, 2017, FDA filed for substantive scientific review six modified risk tobacco product applications (MRTPA) from R.J. Reynolds for six styles of Camel Snus smokeless tobacco products referenced above. We are writing to complain about the public comment process for review of the above-referenced docket.
December 21, 2017
We are in the process of migrating the Tobacco Center website to a new website and it is very difficult to capture and transfer comments. As a result no comments made between now and when the new site is up (around a week or two) will be considered for posting.
Replies will be considered for posting when the new site is up.
December 21, 2017
We submitted this letter to the FDA Tobacco Products Scientific Committee on the PMI MRTP application. A PDF of the letter, including all the UCSF public comments to date on the IQOS is available here.
December 20, 2017
Tobacco Products Scientific Advisory Committee
c/o Caryn Cohen
Office of Science
Center for Tobacco Products
Food and Drug Administration
Document Control Center
Bldg. 71, Rm. G335
10903 New Hampshire Ave.
Silver Spring, MD 20993–0002
[email protected]
Re: 82 FR 27487, Docket no. FDA-2017-D-3001-3002 for Modified Risk Tobacco Product Applications: Applications for IQOS System With Marlboro Heatsticks, IQOS System With Marlboro Smooth Menthol Heatsticks, and IQOS System With Marlboro Fresh Menthol Heatsticks Submitted by Philip Morris Products S.A.; Availability
Dear Committee Members:
We are submitting the 10 public comments that we have submitted to the above-referenced docket on Philip Morris’s modified risk tobacco product applications (MRTPA) for IQOS.
It is barely a month before the meeting and the docket on IQOS has not even closed.
December 12, 2017
Lauren Lempert and I submitted this letter to Mitch Zeller at the FDA by email and submission to the PMI IQOS dockett (tracking number 1k1-90bh-d1uh ). A PDF of the letter is here.
December 12, 2017
Mr. Mitchell Zeller
Director, Center for Tobacco Products
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Re: 82 FR 27487, Docket no. FDA-2017-D-3001-3002 for Modified Risk Tobacco Product Applications: Applications for IQOS System With Marlboro Heatsticks, IQOS System With Marlboro Smooth Menthol Heatsticks, and IQOS System With Marlboro Fresh Menthol Heatsticks Submitted by Philip Morris Products S.A.; Availability
Dear Mr. Zeller:
We are writing to complain about the public comment process for the above-referenced docket on Philip Morris’s modified risk tobacco product applications (MRTPA) for IQOS.